Epithelial growth factor receptor status in primary and recurrent ovarian cancer

Success of epidermal growth factor receptor (EGFR) targeting agents in different cancer types is related to EGFR gene mutations and/or copy number gains. We investigated the EGFR gene status and protein expression by DNA mutational analysis, fluorescence in situ hybridization (FISH), and immunohisto...

Full description

Saved in:

Bibliographic Details
Published in:	Modern pathology 2006-04, Vol.19 (4), p.607-610
Main Authors:	Stadlmann, Sylvia, Gueth, Uwe, Reiser, Ulrich, Diener, Pierre-Andre, Zeimet, Alain Gustave, Wight, Edward, Mirlacher, Martina, Sauter, Guido, Mihatsch, Michael J, Singer, Gad
Format:	Article
Language:	eng
Subjects:	Adult Aged amplification Cystadenocarcinoma, Serous - genetics Cystadenocarcinoma, Serous - metabolism Cystadenocarcinoma, Serous - pathology epidermal growth factor receptor ErbB Receptors - analysis ErbB Receptors - genetics Female fluorescence in situ hybridization Gene Dosage Humans Immunohistochemistry In Situ Hybridization, Fluorescence Middle Aged Mutation Neoplasm Recurrence, Local Ovarian cancer Ovarian Neoplasms - genetics Ovarian Neoplasms - metabolism Ovarian Neoplasms - pathology Tissue Array Analysis tissue microarray
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Success of epidermal growth factor receptor (EGFR) targeting agents in different cancer types is related to EGFR gene mutations and/or copy number gains. We investigated the EGFR gene status and protein expression by DNA mutational analysis, fluorescence in situ hybridization (FISH), and immunohistochemistry in tumor tissues from 80 patients with primary and corresponding recurrent ovarian serous carcinomas. The patients were classified into six groups with ascending EGFR gene copy numbers. EGFR amplification and high polysomy (FISH+) was present in a significant fraction of the primary (20%) and recurrent (22%) ovarian carcinomas. On mutational analysis, only one tumor with a silent EGFR mutation was observed, and this was the only carcinoma with high-level amplification. EGFR protein immunoexpression was seen in 28% of primary and 33% of recurrent carcinomas and correlated to amplification in the primary tumors (P=0.003). In recurrent carcinoma, moderate and strong EGFR expression was associated with amplification (P=0.034). These molecular events potentially have impact on the responsiveness to EGFR targeting agents in ovarian cancer.
ISSN:	0893-3952 1530-0285